Previous 10 | Next 10 |
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 202...
2023-10-13 09:59:46 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals...
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Cata...
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Pat...
2023-09-08 17:18:18 ET More on Catalyst Pharmaceuticals Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals Historical earnings data for Catalyst Pharmaceuticals Financial information for Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Jour...
2023-08-30 17:36:00 ET Summary Catalyst Pharmaceuticals reported a significant increase in product revenues, with a YoY growth of 87.5% in Q2 2023. The company maintains a strong financial position with $178.8M in cash and cash equivalents and no immediate need for additional fina...
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare disea...
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseas...
2023-08-10 11:37:06 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Alicia Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer ...
2023-08-09 16:23:21 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.53 beats by $0.24 . Revenue of $99.58M (+87.5% Y/Y) beats by $7.87M . Achieved all-time high total revenues of $99.6 million for Q2 2023, an 87.5% YoY increase...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...